CM
MRNS

Caption Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Caption Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-320,600
Closed -$3.48M – 1763
2023
Q4 		$3.48M Buy
+320,600
New +$2.4M 0.05% 459
2023
Q3 		– Sell
-50,000
Closed -$543K – 1624
2023
Q2 		$543K Hold
50,000
– – 0.01% 803
2023
Q1 		$345K Buy
50,000
+43,500
+669% +$273K 0.01% 859
2022
Q4 		$25.9K Buy
+6,500
New +$32K ﹤0.01% 1199
2022
Q2 		– Sell
-100,000
Closed -$934K – 1939
2022
Q1 		$934K Buy
+100,000
New +$993K 0.01% 1000
2020
Q4 		– Sell
-648,700
Closed -$8.34M – 1299
2020
Q3 		$8.34M Buy
+648,700
New +$5.6M 0.2% 120
2019
Q4 		– Sell
-11,250
Closed -$69K – 1031
2019
Q3 		$69K Hold
11,250
– – ﹤0.01% 643
2019
Q2 		$187K Buy
+11,250
New +$195K 0.01% 573

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Caption Management's MRNS Position: Q3 2024 in Review

Caption Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 200 shares — an estimated $234 sold.

Caption Management first reported a position in MRNS in Q3 2018 and held it in 16 quarters. The position peaked at $1.89M in Q3 2018. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • Caption Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • Caption Management sold 200 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $234.
  • Caption Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2018 and held it in 16 quarters.
  • Caption Management's Marinus Pharmaceuticals, Inc position peaked at $1.89M in Q3 2018.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on Caption Management's 13F filing for Q3 2024, filed 14 Nov 2024.